Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity

Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.